Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAMS-Extension long-term atacicept safety in relapsing multiple sclerosis
2008-005021-11Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Dec 2008
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atacicept in multiple sclerosis (MS), sponsored by Merck Serono. Primary endpoints: Long-term safety and tolerability of atacicept, Long-term relapse activity and 1 more. Started Dec 2008; status: completed.
02
Drugs
atacicept
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-005021-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005021-11.